ScinoPharm Invests in High Potency Facility

Active pharmaceutical ingredient (API) manufacturer ScinoPharm Taiwan (Shanhua, Taiwan) says it will invest NT$1.13 billion ($38 million) to build a high potency cytotoxic injectable plant for oncological injectable products at the company's site at the Tainan Science Park in Taiwan. ScinoPharm, which is a global leader in supplying oncological APIs for injectable products, currently has the highest number of oncological APIs within the generic industry, the company says. “By expanding into the field of oncological injectable formulation, ScinoPharm will be...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers